B.C. Pacific Capital CL A Sv (BPQ.A) Quote

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Harrow Announces Second Quarter 2024 Financial Results

Second Quarter 2024 and Recent Selected Highlights: Record revenues of $48.9 million GAAP net loss of $(6.5) million Adjusted EBITDA of $8.8 million Cash and cash equivalents of $71.0 million as...

Harrow To Report Second Quarter 2024 Financial Results After Market Close on August 7, 2024

Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on August 8, 2024 Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it will...

Harrow to Attend 2024 ASRS Annual Meeting

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that its management team would attend the 2024 American Society of Retina Specialists (ASRS) Annual...

Harrow Enters into 340B Prime Vendor Program Contract with Apexus™ for IHEEZO® and Other Key Harrow Products

Contract Enhances Purchasing Power for 340B Prime Vendor Program (PVP) Participants; Aligns with Harrow’s Mission to Make Its Products Accessible and Affordable Harrow (Nasdaq: HROW), a leading...

Harrow Provides TRIESENCE® Relaunch Update

Successful Manufacture of TRIESENCE PPQ Batch Leads to Scheduling of Remaining Process Qualification Steps, Initial Inventory Build, and Pre-Commercial Activities Harrow (Nasdaq: HROW), a leading...

Melt Pharmaceuticals Announces First Patient Dosed in Pivotal Phase 3 Program of Its Lead Product Candidate, MELT-300, for Needle- and Opioid-Free Sedation in Patients Undergoing Cataract Surgery

Topline Readout Expected in Q4 2024 Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today announced that the...

Harrow Announces 52-Week Data from VEVYE® ESSENCE-2 Open-Label Extension Study

Data Demonstrates Sustained Safety and Efficacy in Treating Signs and Symptoms of Dry Eye Disease Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, is pleased to...

Harrow to Present at Two Investor Conferences in May

Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two investor conferences in May: B. Riley...